このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Bora Pharmaceuticals バランスシートの健全性

財務の健全性基準チェック /56

Bora Pharmaceuticalsの総株主資本はNT$11.5B 、総負債はNT$8.2Bで、負債比率は71.5%となります。総資産と総負債はそれぞれNT$30.7BとNT$19.2Bです。 Bora Pharmaceuticalsの EBIT はNT$4.6Bで、利息カバレッジ比率46.6です。現金および短期投資はNT$8.4Bです。

主要情報

71.5%

負債資本比率

NT$8.20b

負債

インタレスト・カバレッジ・レシオ	46.6x
現金	NT$8.39b
エクイティ	NT$11.46b
負債合計	NT$19.20b
総資産	NT$30.66b

財務の健全性に関する最新情報

Recent updates

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Jun 13

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Apr 10

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Apr 08

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Mar 14

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Apr 30

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Mar 17

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Feb 17

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Jan 27

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Jan 19

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Dec 29

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Dec 09

財務状況分析

短期負債: 6472の短期資産 ( NT$15.9B ) が短期負債 ( NT$13.1B ) を超えています。

長期負債: 6472の短期資産 ( NT$15.9B ) が長期負債 ( NT$6.1B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 6472総負債よりも多くの現金を保有しています。

負債の削減: 6472の負債対資本比率は、過去 5 年間で38.2%から71.5%に増加しました。

債務返済能力: 6472の負債は営業キャッシュフローによって十分にカバーされています ( 47.2% )。

インタレストカバレッジ: 6472の負債に対する利息支払いは EBIT ( 46.6 x coverage) によって十分にカバーされています。

Bora Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Recent updates

Investor sentiment improves as stock rises 15%

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

First quarter 2024 earnings: EPS exceeds analyst expectations

Bora Pharmaceuticals Co., LTD. to Report Q1, 2024 Results on May 14, 2024

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Investor sentiment improves as stock rises 18%

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Consensus revenue estimates increase by 11%

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Bora Pharmaceuticals Co., LTD., Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS misses analyst expectations

Price target increased by 17% to NT$827

Price target increased by 7.7% to NT$713

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 11%

SunWay Biotech Co., LTD. (TPEX:1271) agreed to acquire Bora Health Inc from Bora Pharmaceuticals Co., LTD. (TPEX:6472).

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 15%

Upcoming dividend of NT$8.00 per share at 1.0% yield

Bora Pharmaceuticals Co., Ltd. Elects Lin Hsin-I as Independent Director

Bora Pharmaceuticals Co., LTD. to Report Q1, 2023 Results on May 17, 2023

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates increase by 18%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 31%

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Price target increased to NT$231

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.50 per share

Bora Pharmaceuticals Co., LTD. Announces Common Stock Cash Dividend, Payable on August 2, 2022

Bora Pharmaceuticals Co., LTD. announced that it has received TWD 800 million in funding

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target increased to NT$302

Third quarter 2021 earnings released: EPS NT$2.02 (vs NT$0.82 in 3Q 2020)

Price target increased to NT$276

Investor sentiment deteriorated over the past week

Upcoming dividend of NT$2.00 per share

Second quarter 2021 earnings released: EPS NT$2.54 (vs NT$0.80 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$6.18 (vs NT$0.84 in 1Q 2020)

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Investor sentiment improved over the past week

Consensus revenue estimates increase to NT$5.23b

Price target increased to NT$219

Full year 2020 earnings released: EPS NT$10.76 (vs NT$6.08 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Investor sentiment improved over the past week

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

New 90-day low: NT$157

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Investor sentiment deteriorated over the past week

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Investor sentiment improved over the past week

New 90-day high: NT$199

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Price target raised to NT$191

New 90-day high: NT$194

財務の健全性基準チェック /56